TherapeuticsMD Inc (NASDAQ:TXMD) has received a consensus broker rating score of 1.00 (Strong Buy) from the four brokers that cover the stock, Zacks Investment Research reports. Four research analysts have rated the stock with a strong buy recommendation.
Brokerages have set a 12-month consensus price objective of $15.63 for the company and are expecting that the company will post ($0.11) EPS for the current quarter, according to Zacks. Zacks has also given TherapeuticsMD an industry rank of 113 out of 265 based on the ratings given to its competitors.
A number of analysts have weighed in on the stock. Zacks Investment Research upgraded shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a research note on Saturday, September 3rd. Noble Financial reiterated a “buy” rating and issued a $17.50 price target on shares of TherapeuticsMD in a research note on Monday, July 11th.
Shares of TherapeuticsMD (NASDAQ:TXMD) opened at 6.23 on Friday. The company’s 50-day moving average is $6.68 and its 200-day moving average is $7.66. The company’s market cap is $1.22 billion. TherapeuticsMD has a 12-month low of $5.18 and a 12-month high of $11.26.
TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by $0.01. The business had revenue of $4.40 million for the quarter, compared to analyst estimates of $5.63 million. The business’s quarterly revenue was down 8.3% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.16) EPS. Equities research analysts predict that TherapeuticsMD will post ($0.43) earnings per share for the current year.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare product company. The Company’s segment is creating and commercializing products for women. It is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. Its drug candidates are created using its SYMBODA hormone technology, which enables the administration of hormones with high bioavailability alone or in combination.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.